The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Hao Wang
No Relationships to Disclose
 
Michael Thomas Schweizer
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Pfizer (Inst); Roche (Inst); Zenith Epigenetics (Inst)
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Omnitura
Research Funding - Lilly (Inst)
 
Benjamin A. Teply
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Inovio Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to drug delivery technology with royalties paid via MIT
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru; Veru; Veru
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi; Veru
 
Jun Luo
Consulting or Advisory Role - Janssen Oncology; Sun Pharma
Research Funding - Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Orion (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licensed to Tokai Pharmaceuticals. (Inst); Jun Luo is a co-inventor of a technology licensed to A&G Pharmaceuticals (Inst); Jun Luo is a co-inventor of a technology licensed to Qiagen (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Samuel R. Denmeade
Stock and Other Ownership Interests - Sophiris Bio
Consulting or Advisory Role - Sophiris Bio
Travel, Accommodations, Expenses - Sophiris Bio